Early occurrence of red blood cell alloimmunization in patients with sickle cell disease

American Journal of Hematology

Volumn 91, Issue 8, 2016, Pages 763-769

  Sins, Joep W R ^a,b   Biemond, Bart J ^b   van den Bersselaar, Sil M ^a,b   Heijboer, H ^a   Rijneveld, Anita W ^c   Cnossen, Marjon H ^d   Kerkhoffs, Jean Louis H ^e   van Meurs, Alfred H ^e   von Ronnen, F B ^a,b   Zalpuri, Saurabh ^f   de Rijke, Yolanda B ^c   Ellen van der Schoot, C ^g   de Haas, Masja ^g   van der Bom, Johanna G ^f   Fijnvandraat, Karin ^a,g  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e HAGA HOSPITAL   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY;

ADULT; ALLOIMMUNIZATION; ANTIBODY PRODUCTION; ARTICLE; COHORT ANALYSIS; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SICKLE CELL ANEMIA;

EID: 84978198737     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24397     Document Type: Article

References (54)

1. Riddington C, Wang W. Blood transfusion for preventing stroke in people with sickle cell disease. Cochrane Database Syst Rev 2002.
2. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: Pathophysiology, risk factors, and transfusion management. Blood 2012; 120:528–537.
3. Drasar E, Igbineweka N, Vasavda N, et al. Blood transfusion usage among adults with sickle cell disease - A single institution experience over ten years. Br J Haematol 2011; 152:766–770.
4. Vidler JB, Gardner K, Amenyah K, et al. Delayed haemolytic transfusion reaction in adults with sickle cell disease: A 5-year experience. Br J Haematol 2015; 169:746–753.
5. Zalpuri S, Zwaginga JJ, le Cessie S, et al. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012; 102:144–149.
6. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91:1000–1005.
7. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322:1617–1621.
8. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76:1431–1437.
9. Ameen R, Al Shemmari S, Al-Bashir A. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion. Transfusion 2009; 49:1649–1654.
10. Castro O, Sandler SG, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: Theoretical and practical implications. Transfusion 2002; 42:684–690.
11. Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48:2069–2076.
12. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: A review of a 14-year experience from a single center (CME). Transfusion 2011; 51:1732–1739.
13. Tahhan H, Holbrook C, Braddy L, et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994; 34:562–569.
14. O'Suoji C, Liem RI, Mack AK, et al. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer 2013; 60:1487–1491.
15. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: A multicenter transfusion trial. Transfusion 2001; 41:1086–1092.
16. Mijovic A, Perera IGJ, Thein SL. Red blood cell alloimmunization in sickle cell disease-prevalence and trends: A single-center cross-sectional study from United Kingdom. Transfusion 2013; 53:3279–3280.
17. Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2013.
18. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159:394–404.
19. Bao W, Zhong H, Manwani D, et al. Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease. Am J Hematol 2013; 88:736–740.
20. Bao W, Yu J, Heck S, et al. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 2009; 113:5624–5627.
21. Alarif L, Castro O, Ofosu M, et al. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin Immunol Immunopathol 1986; 38:178–183.
22. Hoppe C, Klitz W, Vichinsky E, et al. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol 2009; 84:462–464.
23. Tatari-Calderone Z, Minniti CP, Kratovil T, et al. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol 2009; 47:64–70.
24. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2014.
25. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122:1062–1071.
26. Tournamille C, Meunier-Costes N, Costes B, et al. Partial C antigen in sickle cell disease patients: Clinical relevance and prevention of alloimmunization. Transfusion 2010; 50:13–19.
27. Murao M, Viana MB. Risk factors for alloimmunization by patients with sickle cell disease. Brazilian J Med Biol Res 2005; 38:675–682.
28. Miller ST, Kim H-Y, Weiner DL, et al. Red blood cell alloimmunization in sickle cell disease: Prevalence in 2010. Transfusion 2012.
29. Sarnaik S, Schornack J, Lusher JM. The incidence of development of irregular red cell antibodies in patients with sickle cell anemia. Transfusion 1986; 26:249–252.
30. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003; 158:915–920.
31. Schonewille H, van de Watering LMG, Loomans DSE, et al. Red blood cell alloantibodies after transfusion: Factors influencing incidence and specificity. Transfusion 2006; 46:250–256.
32. Aken W van, Buiting A, Casparie A, et al. Richtlijn Bloedtransfusie. 2004.
33. Schonewille H, Brand A. Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. Br J Haematol 2005; 129:151–156.
34. van de Watering L, Hermans J, Witvliet M, et al. HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: A randomized controlled trial. Transfusion 2003; 43:765–771.
35. Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58:50–55.
36. Gupta R, Singh DK, Singh B, et al. Alloimmunization to red cells in thalassemics: Emerging problem and future strategies. Trans Apher Sci 2011; 45:167–170.
37. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L, et al. Alloimmunization to red cell antigens in thalassemia: Comparative study of usual versus better-match transfusion programmes. Vox Sang 1987; 52:95–98.
38. Natukunda B, Brand A, Schonewille H. Red blood cell alloimmunization from an African perspective. Curr Opin Hematol 2010; 17:565–570.
39. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: Evidence for a distinct population of immunologic responders. Blood 2008; 112:2546–2553.
40. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: Evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica 2014; 99:e115–e117.
41. Abou-Elella AA, Camarillo TA, Allen MB, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995; 35:931–935.
42. Upham JW, Lee PT, Holt BJ, et al. Development of interleukin-12-producing capacity throughout childhood. Infect Immun 2002; 70:6583–6588.
43. Clerici M, DePalma L, Roilides E, et al. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest 1993; 91:2829–2836.
44. Velilla PA, Rugeles MT, Chougnet CA. Defective antigen-presenting cell function in human neonates. Clin Immunol 2006; 121:251–259.
45. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009; 114:5117–5125.
46. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood 2000; 96:3369–3373.
47. Ahmed AM, Hasan NS, Ragab SH, et al. Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients. Arch Med Sci 2010; 6:592–598.
48. Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity 2013; 39:806–818.
49. Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000; 40:1127–1131.
50. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009; 49:505–512.
51. NIH. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 - NHLBI, NIH. 2014.
52. Hendrickson JE, Desmarets M, Deshpande SS, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 2006; 46:1526–1536.
53. Smith NH, Hod EA, Spitalnik SL, et al. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 2012; 119:1566–1569.
54. NHS. Sickle cell disease in childhood - Standards and guidelines for clinical care. 2010.